Cyto-Facto develops and manufactures CAR-T cell therapies and mesenchymal stem cell products to provide targeted treatments for various cancers and regenerative medicine applications. The company aims to enhance patient outcomes in Japan and beyond through the reliable delivery of cell and gene therapy products.
Funding
$7.6M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
DFounders
Product
Problem
Current cancer and regenerative medicine treatments often lack precise targeting, leading to off-target effects and suboptimal patient outcomes. The reliable and scalable delivery of cell and gene therapies (CGT) remains a significant challenge in these fields.
Solution
Cyto-Facto develops and manufactures targeted cell therapies, including CAR-T cell therapies and mesenchymal stem cell products, designed for specific applications in cancer treatment and regenerative medicine. By focusing on the reliable delivery of these advanced therapies, Cyto-Facto aims to improve patient outcomes. Their approach seeks to provide more precise and effective treatments compared to traditional methods.
Target Audience
The primary target audience includes patients with cancer and individuals requiring regenerative medicine therapies, as well as healthcare providers in Japan and other regions seeking advanced treatment options.
Features
- Development of CAR-T cell therapies for targeted cancer treatment.
- Manufacturing of mesenchymal stem cell products for regenerative medicine applications.
- Focus on reliable and scalable delivery of cell and gene therapies.